Asia Pacific Diabetes Devices Size
The Asia Pacific Diabetes Devices Market reached approximately US$ 7.9 billion in 2025 and is expected to reach nearly US$ 14.8 billion by 2033, growing at a CAGR of 8.2% during the forecast period 2026-2033, driven by the increasing prevalence of diabetes, rising adoption of continuous glucose monitoring (CGM) systems and insulin delivery devices, expanding healthcare infrastructure, and growing awareness regarding early diabetes management across emerging economies such as China, India, and Southeast Asian countries.
Diabetes mellitus, sometimes known as diabetes, is a group of metabolic disorders characterized by a chronically high blood sugar level. Common symptoms include frequent urination, increased thirst, and increased hunger. Diabetes, if untreated, may cause an array of health problems. Acute consequences include diabetic ketoacidosis, hyperosmolar hyperglycemia, and death. Long-term risks include cardiovascular illness, stroke, chronic kidney disease, foot ulcers, nerve damage, eye damage, and cognitive impairment.
Diabetes is classified into three types: type 1 diabetes, type 2 diabetes, and gestational diabetes. Thus, the devices used to monitor the diabetic conditions of patients are called diabetes devices. The increasing prevalence of diabetes and technological advancements primarily drive the market growth.
Market Summary
| Metrics | Details |
| CAGR | 8.2% |
| Market Size | 2025-2033 |
| Market Estimation Forecast Period | 2026-2033 |
| Revenue Units | Value (US$ Mn) |
| Segments Covered | Product Type and Distribution Channel |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter's Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other key Insights. |
For more details on this report - Request for Sample
Asia Pacific Diabetes Devices Dynamics
Increasing Obesity & Growing Attention to Diabetes Care
The demand for the Asia Pacific diabetes devices market is driven by multiple factors. Obesity is a serious issue and a major cause of concern in all of the region's countries. Obesity affects one out of every two adults and one out of every six children.
Obesity and overweight are terms used to describe abnormal or excessive fat buildup in the body, which causes health concerns. Obesity is a prominent component in the prevalence of diabetes in the region's population, as shown in countries such as India, Pakistan, and Sri Lanka, among others, and this reason is a driving force in the diabetic care device market expansion
The usage of diabetic devices is predicted to increase due to the number of government and philanthropic initiatives to boost diabetes awareness. The Ministry of Health and Family Welfare, the WHO Country Office for India, and other partners developed diabetes, a mobile health initiative.
The goal of this public health project is to raise diabetes detection and treatment awareness. Similarly, the WHO and the IDF collaborate to prevent and manage diabetes while also ensuring a good quality of life for people worldwide.
The WHO Diabetes Program, for example, aims to prevent type 2 diabetes, decrease complications, and enhance diabetes patients' quality of life. To improve diabetes prevention and control, NGOs and governments are creating norms and standards, increasing diabetes preventive awareness, and supporting monitoring. As a consequence, it is expected that the increased number of diabetes awareness initiatives will lead to a rise in diabetes diagnosis and, as a result, the usage of diabetic devices.
Moreover, the Asia-Pacific region is witnessing continual expansion over the years. This region holds 60% of the global diabetic population, with India and China accounting for half of those numbers. Even nations such as Indonesia, Thailand, and Japan, along with a few others have seen an increase in diabetic patients recently.
As per ET Healthcare World, in April 2024, a U.S. firm launches a diabetes educational program for Asia Singapore people. IDF projects that 783 million people will be living with diabetes by 2045.
High Cost of the SMBG Devices
The high costs of SMBG (self-monitoring blood glucose) devices, low medical literacy rate & awareness, and blood glucose meters can often produce errors in the results, and strict SMBG manufacturing regulations are expected to hamper the market.
Asia Pacific Diabetes Devices Segment Analysis
The Asia Pacific diabetes devices market is segmented based on product type, and distribution channel.
The insulin delivery devices segment accounted for approximately 45.7% of the Asia Pacific diabetes devices market share
The insulin delivery devices segment is expected to hold the largest market share over the forecast period. Sensors are connected to a transmitter that can send data wirelessly to a dedicated mobile receiving device or smartphone. Using CGMs for people with diabetes and their caregivers and communities is beneficial for managing their blood glucose and insulin levels to maintain their health outcomes.
CGM makes it significantly easier to manage blood glucose levels by decreasing interruptions and allowing for better sleep. It also improves the mental health of patients or caregivers by reducing the overall mental load of managing diabetes, thereby enhancing the market prospects in the coming years.
Also, in June 2023, the digital healthcare business of South Korean internet company Kakao Corporation entered into a collaboration agreement with Dexcom to set up a global digital diabetes management service. The deal combines Kakao Healthcare's capabilities in AI and software technology with Dexcom's continuous glucose monitoring (CGM) devices, Dexcom G6 and G7, which the company is currently seeking approval for from the Ministry of Food and Drug Safety.
According to a 2022 article published in Current Diabetes Reports, an estimated 350,000 persons in the United States use insulin pumps, with 90% having T1D and 10% having T2D. Modern insulin pumps that communicate with CGM devices to automatically adjust insulin in response (automated insulin administration, AID) significantly decrease HbA1c, extend the length of the glycemic target range, and reduce the incidence of hypoglycemic occurrences.
Furthermore, insulin pumps have been associated with higher patient satisfaction when compared to standard MDI treatment. Intelligent insulin pens are also available as an alternative to insulin pump treatment. Smart insulin pens offer the potential to reduce inequalities in technology usage and outcomes, but they have not yet received enough investigation.
The market players are adopting various strategies and innovations to increase market share. For instance, in December 2022, Terumo Corporation announced the reimbursement policies within the Japanese medical insurance system have expanded for the Dexcom G6 CGM system.
Asia Pacific Diabetes Devices Key Players
The major global players in the Asian Pacific delivery devices market include Abbott Laboratories, Acon Laboratories, Bayer AG, Becton, Dickinson and Company, Eli Lilly & Co., Johnson and Johnson, Medtronic Plc, Novo Nordisk A/S, and Sanofi F. Hoffmann-La Roche AG among others.
Key Developments
- On April 18, 2026, major healthcare providers and medical device companies across Asia-Pacific accelerated the adoption of AI-enabled continuous glucose monitoring (CGM) systems and smart insulin delivery devices, particularly in India, China, and Japan. Governments and private healthcare networks are expanding digital diabetes management programs to improve patient outcomes and support remote monitoring solutions across urban and rural populations.
- On March 6, 2026, Medtronic MiniMed strengthened its diabetes care business following the successful IPO of its MiniMed division, supporting further investments in insulin pumps, integrated CGM systems, and automated insulin delivery technologies. The development reflects increasing global investor confidence in advanced diabetes device technologies and their long-term growth potential.
- On February 2026, regional healthcare authorities and diabetes associations across Asia-Pacific increased focus on expanding reimbursement coverage and awareness programs for CGM devices and insulin delivery systems. Rising diabetes prevalence, growing urbanization, and increased healthcare spending continue to drive demand for advanced glucose monitoring technologies across emerging economies including India, China, and Southeast Asia.
- On January 2026, market reports highlighted rapid growth in the Asia-Pacific diabetes devices market, driven by increasing adoption of wearable glucose monitoring devices, smartphone-connected insulin pumps, and digital diabetes management platforms. Technological advancements and expanding telehealth ecosystems are supporting greater penetration of smart diabetes care solutions throughout the region.
- On December 2025, industry participants reported strong expansion of continuous glucose monitoring adoption across India and China, supported by rising awareness regarding real-time glucose tracking and improved chronic disease management. Healthcare providers increasingly integrated CGM technologies into remote patient monitoring and personalized diabetes care programs.
- On November 25, 2025, new industry analysis projected significant expansion of the Asia-Pacific continuous glucose monitoring devices market through 2031, driven by increasing accessibility in underserved markets and rising preference for minimally invasive diabetes monitoring technologies. Manufacturers continued expanding product availability across developing economies to capture rising demand.
- On October 2025, regional and international diabetes device manufacturers accelerated partnerships and digital healthcare collaborations focused on AI-integrated glucose monitoring platforms, smart insulin pens, and connected diabetes ecosystems. These developments strengthened innovation in personalized diabetes management and improved patient adherence across Asia-Pacific healthcare systems.
- On July 2025, several leading diabetes device companies expanded manufacturing and distribution networks across Asia-Pacific to meet growing demand for affordable glucose monitoring and insulin delivery solutions. Local manufacturers in China and India increasingly focused on cost-effective devices and domestic production capabilities to improve market penetration and accessibility.
Why Purchase the Report?
- To visualize the Asia Pacific diabetes devices market segmentation based on product type, distribution channel and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development
- Excel data sheet with numerous data points of Asia Pacific diabetes devices market level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product type mapping is available in excel consisting of key product types of all the major players.
The Asia Pacific diabetes devices market report would provide approximately 36 tables, 20 figures, and 176 Pages.
Target Audience
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
